AcelRx Pharmaceuticals Analyst Ratings
AcelRx Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 632.76% | Alliance Global Partners | → $4.25 | Initiates Coverage On | → Buy |
| 09/25/2023 | 762.07% | HC Wainwright & Co. | $8 → $5 | Maintains | Buy |
| 08/18/2023 | 1279.31% | HC Wainwright & Co. | → $8 | Upgrades | Neutral → Buy |
| 03/14/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 08/17/2021 | 762.07% | HC Wainwright & Co. | $7 → $5 | Maintains | Buy |
| 08/13/2020 | 44.83% | Credit Suisse | $0.69 → $0.84 | Maintains | Underperform |
| 07/20/2020 | 18.97% | Credit Suisse | $1 → $0.69 | Downgrades | Neutral → Underperform |
| 03/17/2020 | 1106.9% | HC Wainwright & Co. | $9 → $7 | Maintains | Buy |
| 11/11/2019 | 244.83% | Credit Suisse | $7 → $2 | Downgrades | Outperform → Neutral |
| 08/05/2019 | 1106.9% | Credit Suisse | → $7 | Assumes | → Outperform |
| 07/10/2019 | — | Credit Suisse | Assumes | → Outperform | |
| 04/24/2019 | — | B. Riley Securities | Initiates Coverage On | → Buy | |
| 02/15/2019 | 1106.9% | Credit Suisse | → $7 | Initiates Coverage On | → Outperform |
| 10/23/2018 | 1451.72% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 10/15/2018 | 1279.31% | Jefferies | → $8 | Upgrades | Hold → Buy |
| 10/10/2018 | 1624.14% | Ladenburg Thalmann | $7 → $10 | Reiterates | Buy → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/02/2023 | 632.76% | 联盟全球合作伙伴 | →$4.25 | 开始承保 | →购买 |
| 09/25/2023 | 762.07% | HC Wainwright公司 | $8→$5 | 维护 | 买 |
| 2023年08月18日 | 1279.31% | HC Wainwright公司 | →$8 | 升级 | 中性→购买 |
| 03/14/2022 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 2021/08/17 | 762.07% | HC Wainwright公司 | $7→$5 | 维护 | 买 |
| 2020年08月13日 | 44.83% | 瑞士信贷 | $0.69→$0.84 | 维护 | 表现不佳 |
| 07/20/2020 | 18.97% | 瑞士信贷 | $1→$0.69 | 评级下调 | 中性→表现不佳 |
| 03/17/2020 | 1106.9% | HC Wainwright公司 | $9→$7 | 维护 | 买 |
| 2019年11月11日 | 244.83% | 瑞士信贷 | $7→$2 | 评级下调 | 跑赢→中性 |
| 2019年08月05日 | 1106.9% | 瑞士信贷 | →$7 | 假设 | →跑赢大盘 |
| 2019年07月10日 | - | 瑞士信贷 | 假设 | →跑赢大盘 | |
| 2019年04月24日 | - | B.莱利证券 | 开始承保 | →购买 | |
| 2019年02月15日 | 1106.9% | 瑞士信贷 | →$7 | 开始承保 | →跑赢大盘 |
| 2018年10月23日 | 1451.72% | B.莱利证券 | →$9 | 开始承保 | →购买 |
| 2018年10月15日 | 1279.31% | 杰富瑞 | →$8 | 升级 | 持有→购买 |
| 2018年10月10日 | 1624.14% | 拉登堡·塔尔曼 | $7→$10 | 重申 | 购买→购买 |
What is the target price for AcelRx Pharmaceuticals (ACRX)?
AcelRx制药公司(ACRX)的目标价是多少？
The latest price target for AcelRx Pharmaceuticals (NASDAQ: ACRX) was reported by Alliance Global Partners on October 2, 2023. The analyst firm set a price target for $4.25 expecting ACRX to rise to within 12 months (a possible 632.76% upside). 3 analyst firms have reported ratings in the last year.
联盟全球合作伙伴于2023年10月2日报道了AcelRx制药(纳斯达克：ACRX)的最新目标价。这家分析公司将目标价定为4.25美元，预计ACRX将在12个月内上涨至(可能上涨632.76)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for AcelRx Pharmaceuticals (ACRX)?
AcelRx制药公司(ACRX)的最新分析师评级是多少？
The latest analyst rating for AcelRx Pharmaceuticals (NASDAQ: ACRX) was provided by Alliance Global Partners, and AcelRx Pharmaceuticals initiated their buy rating.
联盟全球伙伴公司提供了对AcelRx制药公司(纳斯达克代码：ACRX)的最新分析师评级，AcelRx制药公司启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for AcelRx Pharmaceuticals (ACRX)?
AcelRx制药(ACRX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AcelRx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AcelRx Pharmaceuticals was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与AcelRx制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。AcelRx制药的上一次评级是在2023年10月2日提交的，所以你应该预计下一次评级将在2024年10月2日左右的某个时候公布。
Is the Analyst Rating AcelRx Pharmaceuticals (ACRX) correct?
分析师对AcelRx制药公司(ACRX)的评级正确吗？
While ratings are subjective and will change, the latest AcelRx Pharmaceuticals (ACRX) rating was a initiated with a price target of $0.00 to $4.25. The current price AcelRx Pharmaceuticals (ACRX) is trading at is $0.58, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的AcelRx制药(ACRX)评级是以0.00美元至4.25美元的目标价启动的。AcelRx制药公司(AcelRx PharmPharmticals)目前的交易价格为0.58美元，在分析师的预测范围内。